Pertuzumab biosimilars 2025?

What is Pertuzumab and why are biosimilars being pursued?
Pertuzumab (Perjeta) is a humanized monoclonal antibody that blocks HER2 dimerization in breast and gastric cancers. Because of its high cost and the long‑term benefit it provides, many companies are developing biosimilar versions that could lower treatment prices and expand access.

Which companies are developing pertuzumab biosimilars?
Several biologic manufacturers are in the pipeline, including Amgen (with its candidate ABP‑120), Samsung Bioepis (projected candidate “SB‑02”), and MedImmune (under the “MI‑120” program). These programs involve extensive analytical, preclinical and clinical studies to demonstrate similarity to the reference product.

When will the first biosimilar be available in the United States?
The U.S. exclusivity period for Perjeta ends in 2025, after a 12‑year period that began when the drug was approved in 2012. The first biosimilar applications are expected to be filed in 2025, with potential FDA approval in 2026–2027.

What patents are still protecting Pertuzumab?
Key patents covering the antibody sequence and manufacturing processes expire in 2025–2027. The last active patent cited on DrugPatentWatch.com (US 7,221,241) ends 2027, leaving a window for biosimilar entry after 2025.

Have any pertuzumab biosimilars been approved outside the U.S.?
As of 2025, no pertuzumab biosimilar has received regulatory approval in the European Union, Canada, or other major markets. However, the European Medicines Agency’s review timelines suggest that a European approval could follow a U.S. filing if the company files an EMA submission concurrently.

What regulatory hurdles remain for these candidates?
Biosimilar approval requires:
- Demonstration of analytical similarity to the reference drug.
- Non‑clinical safety testing.
- A pivotal clinical trial showing comparable efficacy and safety.
- Manufacturing validation under Good Manufacturing Practice.
Any deviation in glycosylation or folding patterns could delay approval.

How might pricing change once biosimilars enter the market?
Historical trends with trastuzumab biosimilars show initial price reductions of 30‑40 % compared with the originator. If the first pertuzumab biosimilar follows this pattern, patients and payers could see significant savings, though the high cost of monoclonal antibodies will keep absolute prices substantial.

How does the pertuzumab biosimilar landscape compare to trastuzumab biosimilars?
Trastuzumab biosimilars entered the market in 2018 and have since lowered treatment costs in many countries. The pertuzumab market is larger and more complex because it is often used in combination with trastuzumab, increasing the potential for cost savings if both biologics become available as biosimilars.

What should patients and clinicians keep in mind?
- Until a biosimilar is approved, treatment must continue with Perjeta or its combination with trastuzumab.
- Once approved, clinicians should verify biosimilar labeling, including any required post‑marketing surveillance.
- Insurance coverage may change, affecting out‑of‑pocket costs for patients.

Where can I track patent and regulatory status?
DrugPatentWatch.com provides up‑to‑date patent expiration data and lists of active biosimilar candidates for Pertuzumab.

Sources
[1] DrugPatentWatch.com – Pertuzumab patent details and biosimilar pipeline.